Dr. Jeffrey L. Berenberg

Hematology
Tripler Army Medical Center
1 Jarrett White Rd, 
Tripler Amc, HI 
Tripler Army Medical Center
1 Jarrett White Rd, 
Tripler Amc, HI 

Overview

Jeffrey Berenberg is a Hematologist practicing medicine in Tripler Amc, Hawaii.

His clinical expertise encompasses Hairy Cell Leukemia (HCL), Hereditary Spherocytosis, Menopause, and Splenomegaly.

He is actively involved in clinical research, co-authoring 45 peer reviewed articles and participating in 82 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in HI

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Tripler Army Medical Center
1 Jarrett White Rd, Tripler Amc, HI 96859

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

80 Clinical Trials

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Drug, Biological
Study Drugs: Carboplatin, Cisplatin, Durvalumab, Etoposide, Paclitaxel, Pemetrexed Disodium
Study Phase: Phase 3
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
A Phase II Trial of Trametinib With Docetaxel in Patients With KRAS Mutation Positive Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease Following One or Two Prior Systemic Therapies
Enrollment Status: Active_not_recruiting
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drugs: Docetaxel, Trametinib
Study Phase: Phase 2
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial
Enrollment Status: Terminated
Publish Date: September 04, 2026
Intervention Type: Other, Drug
Study Drug: Aspirin
Study Phase: Phase 3
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 02, 2026
Intervention Type: Other
Study Phase: Phase 3
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 3
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Prednisone, Rituximab, Vincristine Sulfate
Study Phase: Phase 2
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab, Sargramostim
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

45 Total Publications

Clinical trial enrollment processes and strategies to enhance clinical trial participation at rural National Cancer Institute Community Oncology Research Program sites.
Clinical trial enrollment processes and strategies to enhance clinical trial participation at rural National Cancer Institute Community Oncology Research Program sites.
Journal: Cancer
Published: June 24, 2026
Similar Doctors
Expertise in
32
conditions
Expertise in
32
conditions
Referral may be required

Oncology Hematology Care Hawaii Inc.

98-150 Kaonohi St Ste B219, 
Aiea, HI 
 (3.3 miles away)
808-539-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Jon Fukumoto is a Hematologist practicing medicine in Aiea, Hawaii. Dr. Fukumoto is highly rated in 32 conditions, according to our data. His clinical expertise encompasses Alpha Thalassemia, Alpha Thalassemia X-Linked Intellectual Disability Syndrome, Thalassemia, Polycythemia Vera, and Bone Marrow Aspiration. Dr. Fukumoto is currently accepting new patients.

Expertise in
17
conditions
Dr. Fariba Navid
Hematology | Oncology
Expertise in
17
conditions
Dr. Fariba Navid
Hematology | Oncology
Referral may be required

Children's Hospital Los Angeles

550 S Beretania St Ste 201, 
Honolulu, HI 
 (4.1 miles away)
323-660-2450
Languages Spoken:
English
See accepted insurances

Fariba Navid is a Hematologist and an Oncologist practicing medicine in Honolulu, Hawaii. Dr. Navid is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Osteosarcoma, Adult Soft Tissue Sarcoma, Ewing Sarcoma, Neuroblastoma, and Bone Marrow Aspiration.

Expertise in
14
conditions
Dr. Nathan J. Robison
Hematology | Oncology
Expertise in
14
conditions
Dr. Nathan J. Robison
Hematology | Oncology
Referral may be required

Children's Hospital Los Angeles

550 S Beretania St Ste 201, 
Honolulu, HI 
 (4.1 miles away)
323-660-2450
Languages Spoken:
English
See accepted insurances

Nathan Robison is a Hematologist and an Oncologist practicing medicine in Honolulu, Hawaii. Dr. Robison is highly rated in 14 conditions, according to our data. His clinical expertise encompasses Neurofibromatosis, Brain Stem Cancer, Posterior Fossa Tumor, and Glioma.

Frequently Asked Questions about Dr. Jeffrey L. Berenberg

How do I make an appointment with Dr. Jeffrey L. Berenberg?

You can book an appointment with Dr. Jeffrey L. Berenberg by calling their office at 808-433-6662. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey L. Berenberg a top-rated expert for Hairy Cell Leukemia (HCL)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey L. Berenberg is classified as an Experienced expert for Hairy Cell Leukemia (HCL), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey L. Berenberg specialize in?

While Dr. Jeffrey L. Berenberg is a Hematology, they have specific expertise in Hairy Cell Leukemia (HCL), Hereditary Spherocytosis, and Menopause. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jeffrey L. Berenberg participate in research or clinical trials?

Yes. Dr. Jeffrey L. Berenberg has published 45 articles and abstracts on conditions like Hairy Cell Leukemia (HCL). You can view a list of Dr. Jeffrey L. Berenberg's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Berenberg's expertise for a condition
ConditionClose
        Want to save this doctor for later?
        Sign Up
        Is this your doctor?
        Find A Second Opinion
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile